QIAGEN Expands Range Of Digital PCR Kits And Services For The Biopharma Industry
Portfolio Pulse from Happy Mohamed
QIAGEN (NYSE:QGEN) has announced the expansion of its digital PCR (dPCR) offering for the development of cell and gene therapies in the biopharma industry. The company has partnered with Niba Labs to offer customized digital PCR assay design services to biopharma customers and also launched the new CGT Viral Vector Lysis Kit. The partnership will allow QIAcuity customers to use the combined expertise of both companies to develop new custom simplex or multiplex assays for the quantification of nucleic acids and to optimize existing qPCR assays for the use in digital PCR.
July 18, 2023 | 8:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
QIAGEN's expansion of its digital PCR offering and partnership with Niba Labs could potentially increase its market share in the biopharma industry. The new CGT Viral Vector Lysis Kit could also attract new customers and increase revenues.
The expansion of QIAGEN's digital PCR offering and its partnership with Niba Labs could potentially increase its market share in the biopharma industry, as it provides innovative solutions for cell and gene therapy development. The launch of the new CGT Viral Vector Lysis Kit could also attract new customers, leading to increased revenues. Therefore, the news is likely to have a positive impact on QIAGEN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100